{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=9&q=hormone-sensitive",
    "query": {
      "q": "hormone-sensitive",
      "condition": "Prostate Cancer",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 158,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=10&q=hormone-sensitive&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=8&q=hormone-sensitive&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T17:06:50.576Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04335682",
      "title": "Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Cancer",
        "Prostate Cancer Metastatic",
        "Prostate Cancer",
        "Castrate Resistant Prostate Cancer",
        "Hormone Sensitive Prostate Cancer",
        "Non-metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance Foundation Trials, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 111,
      "start_date": "2021-08-17",
      "completion_date": "2026-05-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-14T17:06:50.576Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Chicago, Illinois • Fairway, Kansas + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04335682"
    },
    {
      "nct_id": "NCT07779590",
      "title": "A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Castration Sensitive Prostate Cancer (mCSPC)"
      ],
      "interventions": [
        {
          "name": "darolutamide plus androgen deprivation therapy",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide plus androgen deprivation therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4700,
      "start_date": "2026-08-19",
      "completion_date": "2026-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-14T17:06:50.576Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07779590"
    },
    {
      "nct_id": "NCT01875250",
      "title": "Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "PROSTVAC-F (Fowlpox)/TRICOM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PROSTVAC-V (Vaccinia)/TRICOM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Enzalutamide (Xtandi)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 38,
      "start_date": "2013-07-22",
      "completion_date": "2020-02-28",
      "has_results": true,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-10-14T17:06:50.576Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01875250"
    },
    {
      "nct_id": "NCT03016741",
      "title": "Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Castration-Resistant Prostatic Cancer",
        "Metastatic Prostate Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Cancer",
        "Hormone-Refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GnRH agonist/antagonist",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 100,
      "start_date": "2017-03-31",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-10-14T17:06:50.576Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03016741"
    },
    {
      "nct_id": "NCT03871816",
      "title": "A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14532,
      "start_date": "2019-04-22",
      "completion_date": "2022-11-22",
      "has_results": false,
      "last_update_posted_date": "2023-12-11",
      "last_synced_at": "2026-10-14T17:06:50.576Z",
      "location_count": 93,
      "location_summary": "Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 82 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03871816"
    },
    {
      "nct_id": "NCT04927663",
      "title": "11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8",
        "Solid Tumor, Adult",
        "Solid Tumor",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "11C-YJH08",
          "type": "DRUG"
        },
        {
          "name": "Optional Tumor Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Rahul Aggarwal",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2021-08-10",
      "completion_date": "2025-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-05-20",
      "last_synced_at": "2026-10-14T17:06:50.576Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04927663"
    },
    {
      "nct_id": "NCT03860987",
      "title": "Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castrate Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "goserelin",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "18F-DCFPyL",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Radical Prostatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2019-04-30",
      "completion_date": "2026-05-18",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-14T17:06:50.576Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03860987"
    },
    {
      "nct_id": "NCT04557059",
      "title": "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "LHRHa",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Janssen Pharmaceutica N.V., Belgium",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 691,
      "start_date": "2020-11-12",
      "completion_date": "2031-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-14T17:06:50.576Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Jeffersonville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04557059"
    },
    {
      "nct_id": "NCT04493853",
      "title": "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hormone-Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "MALE",
        "summary": "18 Years to 130 Years · Male only"
      },
      "enrollment_count": 1012,
      "start_date": "2020-07-13",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-14T17:06:50.576Z",
      "location_count": 33,
      "location_summary": "Tucson, Arizona • La Jolla, California • Orange, California + 29 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04493853"
    },
    {
      "nct_id": "NCT05276492",
      "title": "Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostate Adenocarcinoma",
        "Prostate Neoplasm",
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Abiraterone Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Prednisone tablet",
          "type": "DRUG"
        },
        {
          "name": "Drug Dairy/Log",
          "type": "OTHER"
        },
        {
          "name": "Low-fat meal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-01-24",
      "completion_date": "2024-11-16",
      "has_results": false,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-10-14T17:06:50.576Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05276492"
    }
  ]
}